滨化集团股份有限公司 董事会秘书工作细则 第四条 董事会秘书应当具备履行职责所必需的财务、管理、法律专业知识， 具有良好的职业道德和个人品德。 第一章 总则 第一条 为了促进滨化集团股份有限公司（以下简称"公司"）的规范运作， 充分发挥董事会秘书的作用，加强对董事会秘书工作的管理与监督，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》 等有关法律、法规、规范性文件、公司股票上市地证券监管规则以及《滨化集团 股份有限公司章程》（以下简称《公司章程》）的规定，制定本工作细则。 第二条 董事会秘书是公司的高级管理人员，为公司与公司股票上市地证券 监管机构的指定联系人。 董事会秘书对公司和董事会负责，承担法律、法规、公司股票上市地证券监 管规则及《公司章程》对公司高级管理人员所要求的义务，享有相应的工作职权， 并获取相应报酬。 第三条 公司应当为董事会秘书履行职责提供便利条件，董事、财务负责人、 其他高级管理人员及相关工作人员应当支持、配合董事会秘书的工作。 董事会秘书为履行职责，有权了解公司的财务和经营情况，参加涉及信息披 露的有关会议，查阅相关文件，并要求公司有关部门和人员及时 ...

滨化集团股份有限公司 第二条 本制度所称期货及衍生品套期保值业务（以下简称"套期保值业 务"）是指为管理公司生产经营中的价格风险而达成与上述风险基本吻合的期货 及衍生品交易的活动。期货交易是指以期货合约或者标准化期权合约为交易标的 的交易活动。衍生品交易是指期货交易以外的，以互换合约、远期合约和非标准 化期权合约及其组合为交易标的的交易活动。 期货及衍生品套期保值业务管理制度 第三条 本管理制度适用于公司及子公司。子公司的套期保值业务由公司统一 管理，未经公司同意不得从事套期保值业务。 第四条 公司套期保值业务应遵守以下基本原则： （一）公司进行套期保值业务以合法、审慎、安全和有效为原则，不以套利、 投机为目的； （二）进行套期保值业务的品种限于公司生产经营所需原材料、产成品； （三）公司进行套期保值的数量不得超过实际采购或销售的数量，期货及衍 生品持仓量不得超过需要保值的数量； 第一章 总则 第一条 为规范滨化集团股份有限公司（以下简称"公司"）的期货及衍生 品套期保值业务的决策、操作及管理程序，发挥套期保值业务在公司原材料采购、 产成品销售中规避价格风险的功能，维护公司及股东利益，依据《上海证券交易 所股 ...

公司董事和高级管理人员从事融资融券交易时，也应遵守本制度并履行相关 询问和报告义务。 公司董事、高级管理人员委托他人代行买卖股票，视作本人所为，也应遵 守本制度并履行相关询问和报告义务。 第三条 本制度所指高级管理人员指公司总经理、副总经理、董事会秘书、 财务负责人或者《公司章程》或董事会决议认定的其他人员。 第四条 公司及董事和高级管理人员在买卖公司股票及其衍生品种前，应知 悉《公司法》《证券法》等法律、法规、规范性文件中关于内幕交易、操纵市场 短线交易、窗口期交易、限售期出售股票、减持比例等禁止行为或限制行为的规 定，不得进行违法违规的交易。 第二章 买卖本公司股票行为的申报 滨化集团股份有限公司 董事和高级管理人员持有和买卖本公司股票管理制度 第一章 总则 第一条 为加强滨化集团股份有限公司(以下简称"公司"或"本公司")对 董事和高级管理人员持有及买卖本公司股票的管理工作，根据《中华人民共和国 公司法》(以下简称《公司法》)、《中华人民共和国证券法》(以下简称《证券法》)、 《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》《上海证券 交易所上市公司自律监管指引第 15 号——股东及董事、高 ...

滨化集团股份有限公司 投资者关系管理制度 第一章 总则 第一条 为了加强滨化集团股份有限公司（以下简称"公司"）与投资者和潜在投 资者（以下统称"投资者"）之间的信息沟通，加深投资者对公司的了解和认同，建 立与投资者之间长期、稳定的良性关系，促进公司诚信自律、规范运作，根据《中华 人民共和国公司法》《中华人民共和国证券法》《关于进一步加强资本市场中小投资者 合法权益保护工作的意见》《上市公司投资者关系管理工作指引》《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律 法规、部门规章、规范性文件、公司股票上市地证券监管规则以及《公司章程》，制 定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流 和诉求处理等工作，加强与投资者之间的沟通，增进投资者对公司的了解和认同，以 提升公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保护投资者目的 的相关活动。 第三条 投资者关系管理的目的： （一）促进公司与投资者之间的良性关系，增进投资者对公司的进一步了解和熟 悉； 1 （三）主动性原则。公司应当主动开展投资者关系管理活动，听取投资者意 ...

滨化集团股份有限公司 独立董事专门会议制度 第一章 总则 第一条 为了促进滨化集团股份有限公司（以下简称"公司"）的规范运作， 充分发挥独立董事在公司治理中的作用，根据《中华人民共和国公司法》《中华 人民共和国证券法》《上海证券交易所股票上市规则》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》《上市公司独立董事管理办法》等法律法规、 部门规章、规范性文件以及《滨化集团股份有限公司章程》（以下简称《公司章 程》），制定本制度。 第二条 独立董事专门会议指全部由独立董事参加的会议。 第二章 议事规则 第三条 公司应当定期或者不定期召开独立董事专门会议。独立董事专门会 议召开需于会议召开前三天通知全体独立董事，紧急情况下，在保证半数以上独 立董事出席的前提下，召开会议可以不受前述通知时间的限制。 第四条 独立董事专门会议由半数以上的独立董事出席方可举行。独立董事 应当亲自出席独立董事专门会议，因故不能亲自出席会议的，应当事先审阅会议 材料，形成明确的意见，并书面委托其他独立董事代为出席。 第五条 独立董事专门会议以现场召开为原则，在保证全体参会独立董事能 够充分沟通并表达意见的前提下，可以依照程序采 ...

滨化集团股份有限公司 募集资金专项存储及使用管理制度 第一章 总则 第一条 为了规范公司募集资金的使用与管理，最大程度地保障投资者的利 益，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证 券法》（以下简称《证券法》）、中国证券监督管理委员会《上市公司募集资金监 管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》以及其他相关法律、法规和规范性文件的规定，结合公 司实际情况，特制定本管理制度。 第二条 本管理制度所指募集资金是指公司通过向不特定对象发行证券(包 括首次发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公 司债券等)以及向特定对象发行证券募集的资金，但不包括公司实施股权激励计 划募集的资金。 第三条 募集资金到位后，公司应及时办理验资手续，由具有证券从业资格 的会计师事务所出具验资报告，并应立即按照募股说明书所承诺的募集资金使用 计划，组织募集资金的使用工作。 第四条 募集资金只能用于公司对外公布的募集资金投向的项目。公司董事 会应制定详细的资金使用计划，做到资金使用的规范、公开和透明。 第五条 公司董事会应根据法 ...

Group 1 - The core viewpoint of the news is that Binhua Co., Ltd. has seen a stock price increase of 1.17%, reaching 4.33 yuan per share, with a total market capitalization of 8.906 billion yuan [1] - Binhua Co., Ltd. is located in Shandong Province and was established on May 21, 1998, with its listing date on February 23, 2010. The company specializes in the production, processing, and sales of organic and inorganic chemical products [1] - The main business revenue composition of Binhua Co., Ltd. includes: Other 56.57%, Propylene Oxide 22.48%, Caustic Soda 15.12%, and Propylene 5.83% [1] Group 2 - Among the top ten circulating shareholders of Binhua Co., Ltd., a fund under Southern Fund holds a significant position. The Southern CSI 1000 ETF (512100) reduced its holdings by 185,500 shares in the third quarter, now holding 18.806 million shares, which is 0.93% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion yuan. Year-to-date returns are 29.2%, ranking 1850 out of 4195 in its category; the one-year return is 24.73%, ranking 2053 out of 4179; and since inception, the return is 14.34% [2]

Group 1 - The National Venture Capital Guidance Fund has officially launched, focusing on early-stage investments in sectors such as integrated circuits, artificial intelligence, aerospace, and low-altitude economy [1][3] - The fund aims to mobilize nearly 1 trillion yuan in local and social capital through its establishment [3] - Three regional sub-funds have been established in Beijing, Shanghai, and Shenzhen, with total scales of 296.46 billion yuan, 471 billion yuan, and 450.5 billion yuan respectively [3] Group 2 - The fund features a three-tier structure: national mother fund, regional mother funds, and sub-funds, with a 20-year duration to promote "patient capital" [4] - Sub-funds are required to invest 70% of their capital in seed and early-stage projects, without regional reinvestment obligations [4] - The private equity and venture capital market is expected to see a significant increase, with a 37.42% year-on-year growth in new registered funds by Q3 2025 [4] Group 3 - State-owned capital dominates the LP market with an investment of 123.12 billion yuan, accounting for 46.8% of total contributions [5] - Corporate investors contribute 44.15 billion yuan, representing 16.8% of the total, primarily from industrial groups and listed companies [5] - Nearly 300 listed companies have engaged in or are planning to establish investment funds this year [5] Group 4 - Companies like Meinian Health and Binhua Co. are actively participating in venture capital by establishing or investing in funds focused on AI, automation, and strategic emerging industries [6][7] - The investment strategies of these companies aim to enhance their competitive edge and align with their long-term strategic goals [6][7] - The establishment of investment funds by listed companies is seen as a way to expand business opportunities and leverage professional investment capabilities [9]

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]

Group 1 - The core viewpoint of the news is that Binhua Co., Ltd. is strategically investing in emerging industries by establishing a partnership with investment institutions to create a sustainable industrial ecosystem [1][2] - The total scale of the targeted fund is 400 million yuan, with Binhua Co., Ltd. contributing 199 million yuan as a limited partner and its subsidiary contributing 1 million yuan as a general partner [1] - The fund will focus on strategic emerging industries such as synthetic biology, new energy, new materials, special chemicals, energy conservation and environmental protection, and high-end equipment manufacturing [1] Group 2 - Binhua Co., Ltd. aims to implement its "technology-driven" strategy through collaboration with professional investment institutions, which will not lead to competition or affect the company's normal operations [2] - The company reported a revenue of 11.148 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 47.35%, while the net profit attributable to shareholders was 192 million yuan, up 1.63% year-on-year [3] - The company has a strong production capacity in the chemical sector, with 610,000 tons of caustic soda and 510,000 tons of propylene oxide, ranking among the top in Shandong province [2][3]